UNASSIGNED: Maternal @entity1031 and a spectrum of placenta-mediated complications including the @entity1468 , @entity1592 , fetal loss, and abruption manifest a shared etiopathogenesis and predisposing risk factors. Furthermore, these @entity2241 are often linked to subsequent maternal health consequences that comprise the @entity209 , namely, @entity1031 , chronic @entity101 , and @entity2175 . Traditionally, several lines of evidence have linked vasoconstriction, excessive @entity715 and @entity32 , and @entity73 at the uteroplacental interface as hallmark features of the placental complications. "Omic" technologies and biomarker development have been largely based upon advances in vascular biology, improved understanding of the molecular basis and biochemical pathways responsible for the clinically relevant diseases, and increasingly robust large cohort and/or registry based studies. Advances in understanding of innate and adaptive immunity appear to play an important role in several pregnancy complications. Strategies aimed at improving prediction of these pregnancy complications are often incorporating hemodynamic blood flow data using non-invasive imaging technologies of the utero-placental and maternal circulations early in pregnancy. Some evidence suggests that a multiple marker approach will yield the best performing prediction tools, which may then in turn offer the possibility of early intervention to prevent or ameliorate these pregnancy complications. Prediction of maternal cardiovascular and non-cardiovascular consequences following pregnancy represents an important area of future research, which may have significant public health consequences not only for @entity65 , but also for a variety of other disorders, such as @entity179 . @entity600 Research (Part C), 2015.    2015 Wiley Periodicals, Inc.

@entity715 during pregnancy: Risks, prevention, and treatment for mother and fetus-harvesting the power of omic technology, biomarkers and in vitro or in vivo models to facilitate the treatment of XXXX .

@entity2175 :: ('MESH:D003924', 'Disease') :: ['type II diabetes'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired trophoblast invasion'] @entity600 :: ('MESH:D000014', 'Disease') :: ['Birth Defects'] @entity1592 :: ('MESH:D005317', 'Disease') :: ['fetal growth restriction'] @entity1468 :: ('MESH:D011225', 'Disease') :: ['pre-eclampsia syndromes'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism'] @entity179 :: ('MESH:D019636', 'Disease') :: ['autoimmune and neurodegenerative diseases'] @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity2241 :: ('MESH:D005315', 'Disease') :: ['maternal and fetal complications']
@entity715 :: (MESH:D013927,Disease) :: ['thrombosis']
